Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
IPO Year: 2014
Exchange: NASDAQ
Website: ocugen.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/15/2024 | $4.00 | Buy | Maxim Group |
| 3/1/2023 | $3.50 | Neutral → Buy | Chardan Capital Markets |
| 8/23/2022 | $5.00 | Buy | Mizuho |
| 6/15/2022 | $8.00 | Buy | ROTH Capital |
| 6/2/2022 | $4.50 | Overweight | Cantor Fitzgerald |
| 2/28/2022 | $10.00 → $8.00 | Buy | HC Wainwright & Co. |
| 7/26/2021 | Outperform | Noble Capital Markets |
4 - Ocugen, Inc. (0001372299) (Issuer)
4 - Ocugen, Inc. (0001372299) (Issuer)
4 - Ocugen, Inc. (0001372299) (Issuer)
4 - Ocugen, Inc. (0001372299) (Issuer)
4 - Ocugen, Inc. (0001372299) (Issuer)
4 - Ocugen, Inc. (0001372299) (Issuer)
3 - Ocugen, Inc. (0001372299) (Issuer)
4 - Ocugen, Inc. (0001372299) (Issuer)
4 - Ocugen, Inc. (0001372299) (Issuer)
4 - Ocugen, Inc. (0001372299) (Issuer)
SC 13G/A - Ocugen, Inc. (0001372299) (Subject)
SC 13G/A - Ocugen, Inc. (0001372299) (Subject)
SC 13G - Ocugen, Inc. (0001372299) (Subject)
SC 13G/A - Ocugen, Inc. (0001372299) (Subject)
SC 13G/A - Ocugen, Inc. (0001372299) (Subject)
SC 13G/A - Ocugen, Inc. (0001372299) (Subject)
SC 13G/A - Ocugen, Inc. (0001372299) (Subject)
SC 13G - Ocugen, Inc. (0001372299) (Subject)
SC 13G/A - Ocugen, Inc. (0001372299) (Subject)
SC 13G - Ocugen, Inc. (0001372299) (Subject)
8-K - Ocugen, Inc. (0001372299) (Filer)
8-K - Ocugen, Inc. (0001372299) (Filer)
8-K - Ocugen, Inc. (0001372299) (Filer)
10-Q - Ocugen, Inc. (0001372299) (Filer)
8-K - Ocugen, Inc. (0001372299) (Filer)
8-K - Ocugen, Inc. (0001372299) (Filer)
8-K - Ocugen, Inc. (0001372299) (Filer)
8-K - Ocugen, Inc. (0001372299) (Filer)
8-K - Ocugen, Inc. (0001372299) (Filer)
10-Q - Ocugen, Inc. (0001372299) (Filer)
MALVERN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen, will speak during the workshop titled, "U.S.-India Biotechnology Cooperation: Realizing Benefits, Reducing Risks." This two-day event will take place from September 9-11, 2024 in New Delhi, India. "It is an honor to join the impressive group of thought leaders in this groundbreaking forum," said Dr. Musunuri. "There are endless opportunities to leverage the bes
MALVERN, Pa., May 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced its expected upcoming inclusion in the Russell 3000® Index, according to preliminary Russell reconstruction information posted on the FTSE Russell website. The newly reconstructed index will take effect after the market closes on June 28, 2024. "Inclusion of Ocugen to the Russell 3000® Index is our latest milestone, adding to what has already been a transformational year for the Company with three of our game-changing modifier gene therapies targeting
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, May 13, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN) investors that a lawsuit was filed on behalf of investors that purchased Ocugen securities. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses. On April 1, 2024, Ocugen filed a Cur
MALVERN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Dr. Huma Qamar as Chief Medical Officer (CMO). "I'm very pleased to name Dr. Qamar as the CMO at Ocugen," said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen. "This appointment recognizes her invaluable contributions to building a strong clinical team, overseeing a well-conducted Phase 1/2 gene therapy trial, and establishing relationships with leading medical and academic institutions and key o
MALVERN, Pa., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Bob Smith, former Senior Vice President, Global Gene Therapy Business at Pfizer, has joined the Company's Business Advisory Board (BAB). The BAB was established in June 2023 to assist in driving public/private partnerships with governments around the world; pursuing business collaborations, partnerships, and licensing opportunities; creating awareness of the Company's differentiated capabilities; and promoting access to the Company's the
Jeffrey Armbrister, Lindy Benton-Moreno, and Connie Collingsworth join the Board of Trustees at the largest national, independent donor-advised fund public charity National Philanthropic Trust (NPT), the largest national, independent public charity that manages donor-advised funds, and one of the leading grantmaking institutions in the U.S., is pleased to announce the appointment of Jeffrey Armbrister, Lindy Benton-Moreno, and Connie Collingsworth to its Board of Trustees. "As NPT continues to grow, innovate, and advance philanthropy around the world, we welcome these three accomplished professionals to our Board of Trustees," said Eileen Heisman, CEO of National Philanthropic Trust. "N
MALVERN, Pa., March 06, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced the appointment of Quan A. Vu to Chief Financial Officer & Chief Business Officer. "Quan has quickly become a tremendous asset for Ocugen and his comprehensive healthcare and financial expertise is providing valuable insight toward reaching our corporate goals," said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen. "With Quan now overseeing both finance and business development, there will be a fully integr
MALVERN, Pa., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Quan A. Vu as Chief Business Officer, responsible for securing new business development partnerships, including in/out licensing opportunities, across the Company's pipeline. "Expanding Ocugen's product portfolio and capabilities, in line with our long-term strategy, is imperative for 2023," said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen. "We are very excited to have Quan join our leadership tea
MALVERN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, as Chief Medical Officer. Arun Upadhyay, PhD, previously Senior Vice President, Research & Development, will now serve as the Company's Chief Scientific Officer, overseeing the development and manufacturing of Ocugen's clinical and commercial product portfolio and evaluating new technologies. "We are extremely pleased to have Dr. Hopkins driving our clinical programs as his expertise acro
MALVERN, Pa., March 23, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines, today announced the appointment of Marna C. Whittington, PhD, to the Board of Directors. Her term became effective March 21, 2022. "We're extremely pleased to welcome Dr. Marna Whittington to the Ocugen board," said Dr. Shankar Musunuri, Chairman of the Board, Chief Executive Officer, and Co-founder of Ocugen. "Her experiences will be exceedingly important to our growth strategy as we progress our modifier gene therapies and vaccine candidate. I also want to thank
Subsequent to quarter-end, closed $30 million in debt financingOCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP) on track to complete enrollment in 1H2025OCU410 is currently in Phase 2 of the Phase 1/2 ArMaDa clinical trial Data and Safety Monitoring Board (DSMB) for the OCU410ST GARDian clinical trial approved enrollment for the second phase of the Phase 1/2 clinical trialNew data on Phase 1/2 clinical trials for OCU410, OCU410ST and OCU400 to be presented at upcoming Clinical Showcase MALVERN, Pa., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel
MALVERN, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call and live webcast to discuss the Company's third quarter 2024 financial results and provide a business update at 8:30 a.m. ET on Friday, November 8, 2024. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID
MALVERN, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host a conference call and live webcast to discuss the Company's second quarter 2024 financial results and provide a business update at 8:30 a.m. ET on Thursday, August 8, 2024. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 7453742We
All three first-in-class modifier gene therapy product candidates currently in the clinic with OCU400 Phase 3 in progressOCU400 on track to meet 2026 Biologics License Application (BLA) and Market Authorization Application (MAA) approval targets MALVERN, Pa., May 14, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today reported first quarter 2024 financial results along with a general business update. "We've experienced several important clinical and regulatory milestones since the beginning of 2024 that we believe
MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series C Preferred Stock, par value $0.01 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on May 20, 2024. The shares of Series C Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on May 22, 2024. The outstanding shares of Series C Preferred Stock will vote toget
MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host a conference call and live webcast to discuss the Company's first quarter 2024 financial results and provide a business update at 8:30 a.m. ET on Tuesday, May 14, 2024. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 8699924Webcast
Received alignment with FDA for broad retinitis pigmentosa (RP) indication in Phase 3 clinical trial of OCU400—first gene therapy program to receive a broad indication for RP. OCU400 Phase 3 clinical trial expected to commence in April 2024. Regenerative Medicine Advanced Therapy (RMAT) designation granted by FDA to OCU400 Completed Cohort 1 dosing for OCU410 and OCU410ST gene therapy clinical studies for geographic atrophy (GA) and Stargardt disease, respectively MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, tod
MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host a conference call and live webcast to provide a business update with certain financials for the year ending December 31, 2023 at 8:30 a.m. ET on Tuesday, April 2, 2024. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 4947142Webca
Conference Call and Webcast Today at 8:30 a.m. ET OCU400 demonstrated favorable safety and tolerability profile in retinitis pigmentosa (RP) and Leber congenial amaurosis (LCA) subjects Completed dosing of three LCA patients including a pediatric patient OCU400 Phase 1/2 study results suggest stabilization or improvement of Best-Corrected Visual Acuity (BCVA) or Multi-Luminance Mobility Testing (MLMT) or Low-Luminance Visual Acuity (LLVA) in treated eyes of 83% (10/12) subjectsStabilization or improvement in MLMT scores from baseline in 86% (6/7) of RHO subjects demonstrated gene-agnostic property of OCU400 modifier gene therapy and its potential benefits in broader RP and LCA subjectsOcuge
MALVERN, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call and live webcast to discuss the Company's third quarter 2023 financial results and provide a business update at 8:30 a.m. ET on Thursday, November 9, 2023. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference
4 - Ocugen, Inc. (0001372299) (Issuer)
4 - Ocugen, Inc. (0001372299) (Issuer)
MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema (DME). "OCU200 has the potential to change the treatment landscape for DME, diabetic retinopathy (DR), and wet age-related macular degeneration (wet AMD) with its unique mechanism of action, binding the active component—tumstatin—to integrin receptors that play a crucial role in disease pathogenesis," said Dr. Shankar Musunuri, Chairma
100% (9/9) of treated evaluable subjects demonstrated improvement or preservation in visual function compared to untreated eyes at both one and two years100% (9/9) of treated evaluable subjects demonstrated improvement or stabilization in mobility testing, which was only performed up to one yearImprovement in visual function was statistically significant (p=0.01, treated vs untreated eyes), regardless of mutation at two yearsFavorable long-term safety and tolerability profile with no serious adverse events related to OCU400 MALVERN, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, a
OCU410 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reported, such as exudation, infectious endophthalmitis, intraocular Inflammation, anterior ischemic optic neuropathy, or vasculitis MALVERN, Pa., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Data and Safety Monitoring Board (DSMB) for the OCU410 ArMaDa clinical trial recently convened and approved continuation of the second phase of the Phase 1/2 study. OCU410 (AAV5-hROR
MALVERN, Pa., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen will present at the Oppenheimer Movers in Rare Disease Summit at the Westin Grand Central, New York on Thursday, December 12, 2024. "I have witnessed firsthand the impact that Ocugen's modifier gene therapies have made in the lives of patients with retinitis pigmentosa (RP) and Stargardt disease, which are inherited retinal diseases with significant unmet medical need," said
MALVERN, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen will present at NobleCon20 – Noble Capital Markets' 20th Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL—taking place December 3 - 4, 2024. "Every year, NobleCon showcases emerging growth companies from a variety of industries to a relevant investor audience," said Dr. Musunuri. "I look forward to shari
MALVERN, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the European Medicines Agency (EMA) has granted orphan medicinal product designation for OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19 (RP19), and cone-rod dystrophy 3 (CORD3). "We are deeply honored to receive orphan medicinal product designation from the EMA for OCU410ST. This recognition brings us one step closer to providing a much-needed option for Stargardt patien
MALVERN, Pa., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced positive preliminary efficacy and safety data from the Phase 1 dose-escalation portion of the Phase 1/2 OCU410 ArMaDa clinical trial for geographic atrophy (GA), secondary to dry age-related macular degeneration (dAMD). Key findings include: no drug-related serious adverse events, reduced lesion growth, preservation of retinal tissue, and—most importantly—there was a positive effect on the functional visual measure of low luminance visual acu
Subsequent to quarter-end, closed $30 million in debt financingOCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP) on track to complete enrollment in 1H2025OCU410 is currently in Phase 2 of the Phase 1/2 ArMaDa clinical trial Data and Safety Monitoring Board (DSMB) for the OCU410ST GARDian clinical trial approved enrollment for the second phase of the Phase 1/2 clinical trialNew data on Phase 1/2 clinical trials for OCU410, OCU410ST and OCU400 to be presented at upcoming Clinical Showcase MALVERN, Pa., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel
MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that on November 6, 2024, the Company entered into a new $30 million credit facility with Avenue Venture Opportunities Fund, L.P., a fund of Avenue Capital Group. Proceeds from the facility are intended for general corporate purposes, capital expenditures, working capital, and general and administrative expenses. The credit facility, which has a term of 4 years, provided $30 million fully funded on the closing date. "We are pleased to enter
Progress on OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP) and new data from Phase 1/2Preliminary safety and efficacy update on OCU410 Phase 1/2 ArMaDa clinical trial for geographic atrophy (GA)Clinical update on OCU410ST Phase 1/2 GARDian clinical trial for Stargardt diseaseFeaturing patients, investigators and thought leaders MALVERN, Pa., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host an in-person Clinical Showcase on Tuesday, November 12, 2024. The event wi
Maxim Group initiated coverage of Ocugen with a rating of Buy and set a new price target of $4.00
Chardan Capital Markets upgraded Ocugen from Neutral to Buy and set a new price target of $3.50
Mizuho initiated coverage of Ocugen with a rating of Buy and set a new price target of $5.00
ROTH Capital resumed coverage of Ocugen with a rating of Buy and set a new price target of $8.00
Cantor Fitzgerald initiated coverage of Ocugen with a rating of Overweight and set a new price target of $4.50
HC Wainwright & Co. reiterated coverage of Ocugen with a rating of Buy and set a new price target of $8.00 from $10.00 previously
Noble Capital Markets initiated coverage of Ocugen with a rating of Outperform
ROTH Capital downgraded Ocugen from Buy to Neutral and set a new price target of $6.00 from $10.00 previously
HC Wainwright & Co. reiterated coverage of Ocugen with a rating of Buy and set a new price target of $10.00 from $12.00 previously
Cantor Fitzgerald downgraded Ocugen from Overweight to Neutral and set a new price target of $11.00 from $15.00 previously